[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,101,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100566711","long-term-characterization-of-gore-tag-conformable-thoracic-stent-graft-with-active-control-system-performance-100566711",false,"NCT06658730","Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance","TGR 23-02TA","Inclusion Criteria:\n\n1. Patient or legally authorized representative (LAR) provides written authorization and\u002For consent per institution and geographical requirements.\n2. Patient has been or is intended to be treated with an eligible registry device.\\*\n3. Patient is age ≥ 18 years at time of informed consent signature.\n\n   * The intent to treat a patient with a Gore product must be made prior to soliciting for possible registry participation. If pre-procedure consent is not feasible due to emergent situation, consent prior to the time of discharge for the index procedure is acceptable.\n\nExclusion Criteria:\n\n1. Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.\n2. Patient with exclusion criteria required by local law.\n3. Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and\u002For investigational device study\\* within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.\n\n   * The term \"study\" does not apply to other observational registries or quality improvement projects. Collection of Registry Device performance from interventional studies may be permissible provided device application is not investigational and there are no novel requirements that alter follow-up conduct (i.e., protocol-mandated interventions).","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","10 Years","OBSERVATIONAL","An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w\u002FAC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.",[25,26,27,28,29,30,31,32],"Vascular Disease","Dissection","Dissection Aortic Aneurysm","Dissection of Aorta","Aneurysm Thoracic","Aneurysm Dissecting","Transection Aorta","Intramural Hematoma",[34,35,36,37,38,39,40,41,42,43,14,44,45],"Endovascular","CTAG","Post-market Registry","Observational","Multi-regional","Real world data","Together Registry","Gore Together Registry","Gore Together Aortic Registry","Conformable Thoracic Stent Graft","TGR23-02TA","GORE TAG","RECRUITING","2026-06-19",{"date":49,"type":50},"2026-06-23","ACTUAL",{"date":52,"type":50},"2025-06-19",{"date":54,"type":20},"2038-08",{"name":56,"class":57},"W.L.Gore & Associates","INDUSTRY",36,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":79,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100618712","gravity-stroke-system-for-recanalization-of-large-vessel-occlusion-strokes-100618712","NCT07335185","Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","GRASSROOT Reg","Inclusion Criteria:\n\n1. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.\n2. Subject has been or will be treated with Supernova and\u002For Neutron devices as the initial device used to remove the thrombus\n3. Subject is willing to participate in a 90-day follow-up visit.\n\nExclusion Criteria:\n\n* Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.",{"count":67,"type":20},3000,"INTERVENTIONAL",[70],"NA","Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.",[73,74,75,76,77,78,25],"Stroke","Ischemic Stroke","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases",[80,81,82,83,84,85,86,87,88,89,73,90],"Mechanical Thrombectomy","Brain","Brain Clot","Cerebral Ischemia","Brain Infarction","Neurovascular Intervention","Revascularization","Reperfusion","Stent Retriever","Supernova","Gravity Medical Technology","NOT_YET_RECRUITING","2026-01-05",{"date":94,"type":50},"2026-01-13",{"date":96,"type":20},"2026-01-01",{"date":98,"type":20},"2030-12-31",{"name":100,"class":57},"Gravity Medical Technology, INC",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100271986","studies-of-neuregulinerbb-signaling-in-human-heart-100271986","NCT02820233","Studies of Neuregulin\u002FERBB Signaling in Human Heart","Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells","Inclusion Criteria:\n\n* Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.\n\nExclusion Criteria:\n\n* less than 18 years of age\n* unwilling or unable to provide informed consent\n* known active myocarditis\n* hypertrophic cardiomyopathy\n* constrictive pericarditis or other significant pericardial disease\n* severe pulmonary hypertension\n* significant renal impairment (Cr \\> 2.5 mg\u002FdL)\n* severe ventricular arrhythmias\n* pregnancy",{"count":109,"type":20},80,"This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.",[112,25,113],"Heart Disease","Heart Failure","2025-03-31",{"date":116,"type":50},"2025-04-03",{"date":118,"type":50},"2015-06",{"date":120,"type":20},"2029-06",{"name":122,"class":123},"Douglas B. Sawyer","OTHER",1,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":68,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":124},"100565778","a-preventive-multidisciplinary-primary-care-intervention-organized-around-a-therapeutic-garden-acceptability-to-patients-suffering-from-cardio-neurovascular-pathology-and-to-those-involved-in-the-action-100565778","NCT06646601","A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering from Cardio-neurovascular Pathology and to Those Involved in the Action.","ArTERRE","Inclusion Criteria:\n\n* age \\> 18 years old;\n* living in the vicinity (+-20 km) of Gap, Laragne-Montéglin, Veynes and Clermont-Ferrand;\n* having been invited to take part in the intervention by the caregivers of the medical structures\n* suffering from an ALD based on CNAM medical criteria (stroke, AOMI, rhythm disorders, valvular heart disease, congenital heart disease, stage I and II heart failure), severe hypertension, chronic coronary disease)\n\nExclusion Criteria:\n\n* heart failure based on CNAM medical criteria (ALD n°5) stage III and IV according to NYHA classification ;\n* with a contraindication to physical activity ;\n* living in an institution;\n* unable to walk more than 100 m independently;\n* Alzheimer's disease or other dementias based on CNAM medical criteria ;\n* with an unlabelled cognitive impairment limiting comprehension.",{"count":133,"type":20},157,[70],"A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.",[25,137,138,139,140,141,142],"Cardiovascular","Atrial Fibrillation (AF)","Heart Failure NYHA Class II","Cardiomyopathies","Stroke, Ischemic","Hypertension Resistant to Conventional Therapy","2024-10-15",{"date":145,"type":50},"2024-10-17",{"date":147,"type":50},"2024-04-09",{"date":149,"type":20},"2026-10",{"name":151,"class":123},"Assistance Publique Hopitaux De Marseille"]